KR101902325B1 - 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제 - Google Patents

아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제 Download PDF

Info

Publication number
KR101902325B1
KR101902325B1 KR1020137028748A KR20137028748A KR101902325B1 KR 101902325 B1 KR101902325 B1 KR 101902325B1 KR 1020137028748 A KR1020137028748 A KR 1020137028748A KR 20137028748 A KR20137028748 A KR 20137028748A KR 101902325 B1 KR101902325 B1 KR 101902325B1
Authority
KR
South Korea
Prior art keywords
compound
tumor
cancer
cells
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137028748A
Other languages
English (en)
Korean (ko)
Other versions
KR20140023333A (ko
Inventor
슝 카이
하이시아오 자이
쳉정 라이
창겡 첸
루디 바오
Original Assignee
쿠리스 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쿠리스 인코퍼레이션 filed Critical 쿠리스 인코퍼레이션
Publication of KR20140023333A publication Critical patent/KR20140023333A/ko
Application granted granted Critical
Publication of KR101902325B1 publication Critical patent/KR101902325B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137028748A 2011-04-01 2012-03-30 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제 Active KR101902325B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US61/470,849 2011-04-01
US201161559489P 2011-11-14 2011-11-14
US61/559,489 2011-11-14
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026847A Division KR20180108848A (ko) 2011-04-01 2012-03-30 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제

Publications (2)

Publication Number Publication Date
KR20140023333A KR20140023333A (ko) 2014-02-26
KR101902325B1 true KR101902325B1 (ko) 2018-09-28

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187026847A Ceased KR20180108848A (ko) 2011-04-01 2012-03-30 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제
KR1020137028748A Active KR101902325B1 (ko) 2011-04-01 2012-03-30 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187026847A Ceased KR20180108848A (ko) 2011-04-01 2012-03-30 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제

Country Status (29)

Country Link
US (7) US8710219B2 (enExample)
EP (2) EP3111938B1 (enExample)
JP (3) JP6242331B2 (enExample)
KR (2) KR20180108848A (enExample)
CN (2) CN103582483B (enExample)
AU (1) AU2012236367B2 (enExample)
BR (1) BR112013025340B1 (enExample)
CA (1) CA2830822C (enExample)
CL (1) CL2013002823A1 (enExample)
CY (2) CY1117785T1 (enExample)
DK (2) DK2694075T3 (enExample)
EA (1) EA022434B9 (enExample)
ES (2) ES2577982T3 (enExample)
HR (2) HRP20160545T1 (enExample)
HU (2) HUE028910T2 (enExample)
IL (2) IL228588A (enExample)
LT (1) LT3111938T (enExample)
ME (2) ME03523B (enExample)
MX (1) MX340577B (enExample)
PE (1) PE20141382A1 (enExample)
PL (2) PL2694075T3 (enExample)
PT (2) PT2694075T (enExample)
RS (2) RS54903B1 (enExample)
SG (2) SG193563A1 (enExample)
SI (2) SI3111938T1 (enExample)
SM (2) SMT201900435T1 (enExample)
TW (1) TWI571469B (enExample)
WO (1) WO2012135571A1 (enExample)
ZA (2) ZA201307082B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
HUE028910T2 (en) 2011-04-01 2017-01-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
DK2780338T3 (en) 2011-11-14 2016-12-19 Ignyta Inc Uracil AS AXL- AND C-MET kinase inhibitors
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
WO2016169417A1 (zh) * 2015-04-21 2016-10-27 成都金瑞长青生物科技有限公司 嘌呤基-n-羟基嘧啶甲酰胺衍生物及其制备方法和用途
CN109476710B (zh) * 2016-07-19 2021-11-23 国立植物基因组研究所 抗真菌病原体的新蛋白质
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2019090331A1 (en) * 2017-11-06 2019-05-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222343A1 (en) * 2009-01-08 2010-09-02 Xiong Cai Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2011130628A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
EP1485348B1 (en) 2002-03-13 2008-06-11 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
ES2347544T3 (es) 2002-03-13 2010-11-02 Janssen Pharmaceutica Nv Inhibidores de histona-desacetilasas.
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
KR101074462B1 (ko) 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 화합물 및 그 용도
US8227636B2 (en) * 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
EP1806347A4 (en) 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
CA2605272C (en) 2005-05-18 2013-12-10 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
EP1979328B1 (en) 2006-01-19 2012-12-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1979326T3 (da) 2006-01-19 2013-01-07 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
EP1981871B1 (en) 2006-01-19 2011-12-28 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
EP2041139B1 (en) 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
MX2009002585A (es) 2006-09-11 2009-08-24 Curis Inc Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc.
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
WO2008033745A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
CN103275067B (zh) 2006-10-28 2015-09-02 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
KR101507182B1 (ko) 2006-12-07 2015-03-30 제넨테크, 인크. 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
TWI499420B (zh) 2006-12-07 2015-09-11 Hoffmann La Roche 肌醇磷脂３-激酶抑制劑化合物及使用方法
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
JP2010522163A (ja) 2007-03-20 2010-07-01 キュリス，インコーポレイテッド 亜鉛結合部位を含むＲａｆキナーゼインヒビター
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
AU2010224125B2 (en) 2009-03-12 2015-05-14 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
ES2609767T3 (es) 2009-10-12 2017-04-24 F. Hoffmann-La Roche Ag Combinaciones de un inhibidor de PI3K y un inhibidor de MEK
HUE028910T2 (en) * 2011-04-01 2017-01-30 Curis Inc Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
BR122022000334B1 (pt) 2011-08-01 2023-03-21 Genentech, Inc Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
CN107735104B (zh) 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222343A1 (en) * 2009-01-08 2010-09-02 Xiong Cai Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2011130628A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
ME03523B (me) 2020-04-20
US10543197B2 (en) 2020-01-28
MX2013011132A (es) 2014-03-12
EP3111938A1 (en) 2017-01-04
CN103582483B (zh) 2016-02-17
PL3111938T3 (pl) 2019-09-30
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
ES2577982T3 (es) 2016-07-19
DK3111938T3 (da) 2019-07-01
US20170304279A1 (en) 2017-10-26
US20220168284A1 (en) 2022-06-02
CN103582483A (zh) 2014-02-12
RS59219B1 (sr) 2019-10-31
ZA201307082B (en) 2015-04-29
KR20140023333A (ko) 2014-02-26
BR112013025340A2 (pt) 2016-12-13
EA022434B1 (ru) 2015-12-30
US11654136B2 (en) 2023-05-23
SMT201900435T1 (it) 2019-09-09
US9249156B2 (en) 2016-02-02
US10111864B2 (en) 2018-10-30
TWI571469B (zh) 2017-02-21
JP2014509653A (ja) 2014-04-21
US20200215039A1 (en) 2020-07-09
US20140243330A1 (en) 2014-08-28
JP2016188255A (ja) 2016-11-04
EA201301114A1 (ru) 2014-04-30
HRP20191091T1 (hr) 2019-09-20
NZ705039A (en) 2016-03-31
WO2012135571A1 (en) 2012-10-04
CA2830822A1 (en) 2012-10-04
CN105461736B (zh) 2018-06-12
CY1117785T1 (el) 2017-05-17
TW201247678A (en) 2012-12-01
SMT201600179B (it) 2016-08-31
JP6275784B2 (ja) 2018-02-07
HRP20160545T1 (hr) 2016-06-17
AU2012236367A1 (en) 2013-04-18
US11135205B2 (en) 2021-10-05
US8710219B2 (en) 2014-04-29
SG10201602569RA (en) 2016-05-30
CN105461736A (zh) 2016-04-06
IL248597B (en) 2018-04-30
CL2013002823A1 (es) 2014-04-11
KR20180108848A (ko) 2018-10-04
PE20141382A1 (es) 2014-11-04
MX340577B (es) 2016-07-13
JP6242331B2 (ja) 2017-12-06
IL228588A (en) 2016-11-30
SG193563A1 (en) 2013-11-29
AU2012236367B2 (en) 2014-10-09
PT2694075T (pt) 2016-07-11
PL2694075T3 (pl) 2016-09-30
CY1121825T1 (el) 2020-07-31
US20130090335A1 (en) 2013-04-11
EA022434B9 (ru) 2016-02-29
IL228588A0 (en) 2013-12-31
ME02451B (me) 2016-09-20
SI3111938T1 (sl) 2019-08-30
EP2694075A4 (en) 2014-10-01
HK1194969A1 (zh) 2014-10-31
ZA201406167B (en) 2015-03-25
IL248597A0 (en) 2016-12-29
EP3111938B1 (en) 2019-05-08
DK2694075T3 (en) 2016-08-01
JP2018052987A (ja) 2018-04-05
US9657032B2 (en) 2017-05-23
PT3111938T (pt) 2019-07-10
LT3111938T (lt) 2019-06-25
CA2830822C (en) 2018-10-02
US20190091211A1 (en) 2019-03-28
US20160185796A1 (en) 2016-06-30
NZ615586A (en) 2015-02-27
RS54903B1 (sr) 2016-10-31
SI2694075T1 (sl) 2016-07-29
EP2694075A1 (en) 2014-02-12
EP2694075B1 (en) 2016-04-27
BR112013025340B1 (pt) 2021-12-21
ES2733128T3 (es) 2019-11-27

Similar Documents

Publication Publication Date Title
KR101902325B1 (ko) 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제
HK1232775A1 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
HK1232775B (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
HK1194969B (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AU2014280913A1 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
NZ705039B2 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
NZ615586B2 (en) Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8